Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.
EGFR‐mutated lung cancer
case report
osimertinib
pulmonary tuberculosis
rifampicin
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
revised:
14
04
2024
received:
26
01
2024
accepted:
18
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.
Identifiants
pubmed: 38698706
doi: 10.1111/1759-7714.15324
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.
Références
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re‐estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.
Li SJ, Li YF, Song WM, Zhang QY, Liu SQ, Xu TT, et al. Population aging and trends of pulmonary tuberculosis incidence in the elderly. BMC Infect Dis. 2021;21:302.
Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First‐line gefitinib in patients aged 75 or older with advanced non‐small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7:1417–1422.
Shu CC, Liao KM, Chen YC, Wang JJ, Ho CH. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep. 2019;9:11901.
Itano J, Higo H, Ohashi K, Makimoto G, Nishii K, Hotta K, et al. Successful re‐administration of osimertinib in osimertinib‐induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review. Intern Med. 2020;59:823–828.
Lee HY, Kim JW, Yeo CD. A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non‐small cell lung cancer. J Thorac Dis. 2017;9:E709–E713.
Xie Y, Su N, Zhou W, Lei A, Li X, Li W, et al. Concomitant pulmonary tuberculosis impair survival in advanced epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma patients receiving EGFR‐tyrosine kinase inhibitor. Cancer Manag Res. 2021;13:7517–7526.
Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44:1067–1081.
Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro CJ, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84:1156–1169.
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor‐resistant non‐small‐cell lung cancer. N Engl J Med. 2015;372(18):1689–1699.
Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical pharmacokinetics and pharmacodynamics of Afatinib. Clin Pharmacokinet. 2017;56(3):235–250.
Yamasue M, Komiya K, Usagawa Y, Umeki K, Nureki SI, Ando M, et al. Factors associated with false negative interferon‐γ release assay results in patients with tuberculosis: a systematic review with meta‐analysis. Sci Rep. 2020;10(1):1607.